Poxel Adds $17M in Series B for Diabetes Drug Imeglimin
Poxel SA raised €13 million (US$17.3 million) in a Series B round that is intended to see its lead Type II diabetes treatment, imeglimin, through Phase IIb and into the arms of a commercialization partner.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter